Moderna Announces Proposed Public Offering of Shares of Common Stock (Seite 3) | Diskussion im Forum
eröffnet am 20.05.20 01:15:44 von
neuester Beitrag 31.05.24 20:15:10 von
neuester Beitrag 31.05.24 20:15:10 von
Beiträge: 265
ID: 1.325.035
ID: 1.325.035
Aufrufe heute: 1
Gesamt: 25.211
Gesamt: 25.211
Aktive User: 0
ISIN: US60770K1079 · WKN: A2N9D9 · Symbol: MRNA
133,58
EUR
-1,52 %
-2,06 EUR
Letzter Kurs 04.06.24 Tradegate
Neuigkeiten
| Titel |
|---|
04.06.24 · wallstreetONLINE Redaktion |
| Moderna Aktien jetzt im kostenlosen Demokonto handeln!Anzeige |
03.06.24 · Business Wire (engl.)  |
03.06.24 · wallstreetONLINE Redaktion |
03.06.24 · Roland Jegen Anzeige |
Pandemiegefahr : Vogelgrippe-Welle voraus? 9 Aktien, die profitieren könntenWerte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,5000 | +50,00 | |
| 0,9700 | +40,99 | |
| 7,6000 | +40,74 | |
| 5,9900 | +30,79 | |
| 1,4900 | +29,57 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,8500 | -30,34 | |
| 2,2450 | -42,14 | |
| 0,9500 | -43,11 | |
| 1,2660 | -45,55 | |
| 2,0400 | -58,87 |
Beitrag zu dieser Diskussion schreiben
Feedback
nur ein kurzer hickup 😁📊
Antwort auf Beitrag Nr.: 73.958.855 von faultcode am 05.06.23 20:57:4514.12.
WSJ: Moderna Stock Surges After Positive Trial Results
https://www.wsj.com/livecoverage/stock-market-today-dow-jone…
...
Moderna shares rose more than 15% after the company and partner Merck disclosed positive trial results for an experimental mRNA-based treatment for skin cancer.
...
WSJ: Moderna Stock Surges After Positive Trial Results
https://www.wsj.com/livecoverage/stock-market-today-dow-jone…
...
Moderna shares rose more than 15% after the company and partner Merck disclosed positive trial results for an experimental mRNA-based treatment for skin cancer.
...
Antwort auf Beitrag Nr.: 74.503.770 von Samba_an_der_Eckfahne am 19.09.23 11:16:18Der Influenza Impfstoff soll zur nächsten Grippesaison (2024) auf dem Markt sein
Quelle: https://www.webmd.com/cold-and-flu/news/20230913/modernas-mr…
Quelle: https://www.webmd.com/cold-and-flu/news/20230913/modernas-mr…
https://www.deraktionaer.de/artikel/pharma-biotech/moderna-r…
Ist das jetzt schon eine gute Einstiegschance bei Moderna oder geht es noch weiter runter? Hat jemand genauere Kenntnisse zur Pipeline von Moderna? Haben die, außer dem Corona-Impfstoff, noch was im Köcher in absehbarer Zukunft?
Der Kurs liegt aktuell sogar unter dem von Biontech 😲 Zu Corona-Hochzeiten war das undenkbar.
Ist das jetzt schon eine gute Einstiegschance bei Moderna oder geht es noch weiter runter? Hat jemand genauere Kenntnisse zur Pipeline von Moderna? Haben die, außer dem Corona-Impfstoff, noch was im Köcher in absehbarer Zukunft?
Der Kurs liegt aktuell sogar unter dem von Biontech 😲 Zu Corona-Hochzeiten war das undenkbar.
Moderna übertrifft Erwartungen. 6-8 Mrd. $ Verkäufe erwartet statt 5 Mrd. $
https://www.reuters.com/business/healthcare-pharmaceuticals/…
https://www.reuters.com/business/healthcare-pharmaceuticals/…
Trading Spotlight
Antwort auf Beitrag Nr.: 72.120.825 von faultcode am 03.08.22 22:11:055.6.
Moderna and Merck reveal new data on individualized cancer treatment
https://www.morningstar.com/news/marketwatch/20230605219/mod…
...
An investigational individualized neoantigen therapy studied in patients with high-risk melanoma is a collaboration between Moderna and Merck. A previous version of this article referred to it as Moderna's therapy.
Moderna (MRNA) and Merck & Co. (MRK) on Monday released new results from a trial evaluating the companies' mRNA-based investigational individualized neoantigen therapy in combination with Merck's Keytruda in patients with high-risk melanoma. The combined therapy demonstrated a meaningful improvement in distant metastasis-free survival, a key secondary endpoint of the study, the companies said in a release. The results "add to the emerging picture of how individualized neoantigen therapy may advance melanoma treatment and the promise it may hold for other types of cancer," Moderna senior vice president Dr. Kyle Holen said in a statement. The new data are being presented for the first time Monday at the American Society of Clinical Oncology annual meeting in Chicago.
...
Moderna and Merck reveal new data on individualized cancer treatment
https://www.morningstar.com/news/marketwatch/20230605219/mod…
...
An investigational individualized neoantigen therapy studied in patients with high-risk melanoma is a collaboration between Moderna and Merck. A previous version of this article referred to it as Moderna's therapy.
Moderna (MRNA) and Merck & Co. (MRK) on Monday released new results from a trial evaluating the companies' mRNA-based investigational individualized neoantigen therapy in combination with Merck's Keytruda in patients with high-risk melanoma. The combined therapy demonstrated a meaningful improvement in distant metastasis-free survival, a key secondary endpoint of the study, the companies said in a release. The results "add to the emerging picture of how individualized neoantigen therapy may advance melanoma treatment and the promise it may hold for other types of cancer," Moderna senior vice president Dr. Kyle Holen said in a statement. The new data are being presented for the first time Monday at the American Society of Clinical Oncology annual meeting in Chicago.
...
Antwort auf Beitrag Nr.: 72.413.202 von zsclions am 16.09.22 20:51:22Verkaufsgespräche gibt es immer, ob daraus auch Einkaufsgespräche werden, ist bei China die Frage...
moderna führt mit china verkaufsgespräche für den impfstoff.wenn das kommt!!!
Interessante Meldung. Da könnte viel Geld mit von Moderna im Falle eines Sieges generiert werden, wobei derartige Patentstreitigkeiten zumeist über Jahre laufen. Der Zeitpunkt für diese Klagen ist m. E. clever gewählt:
"ROUNDUP 2: Moderna reicht Impfstoff-Patentklagen gegen Biontech/Pfizer ein"
Quelle: https://de.investing.com/news/stock-market-news/roundup-2-mo…
"ROUNDUP 2: Moderna reicht Impfstoff-Patentklagen gegen Biontech/Pfizer ein"
Quelle: https://de.investing.com/news/stock-market-news/roundup-2-mo…
3.8.
Moderna CEO: No ‘Crazy’ Deals. We’re Giving Cash to Shareholders.
https://www.marketwatch.com/articles/moderna-ceo-no-crazy-de…
...
Moderna’s CEO is feeling no pressure to acquire other companies with the $18.1 billion in cash his firm has on hand.
“Investors don’t want us to do something crazy,” the CEO, Stephane Bancel, told Barron’s Wednesday morning, after the company announced earnings results earlier in the day that beat Wall Street expectations.
Some analysts have argued that Moderna needs to undertake big-time M&A as Covid-19 vaccine demand drops worldwide. Bancel disagrees.
“They want us to create value,” he says of his investors. “So we are very happy when we tell them look, we’re returning cash to shareholders, because in the last quarter we didn’t find anything to do. We don’t want to do a big deal for the sake of doing a big deal.”
Instead, Moderna (ticker: MRNA) announced on Wednesday a new $3 billion share buyback, after buying back 9 million shares for $1.3 billion in the second quarter. An additional $1 billion in capacity remains from an earlier share buyback announced in February.
“Why would we, at this stage in the game, want to do something else that looks shiny, when we’re so close to our potentially amazing assets,” Bancel says.
...
$MRNA vs $BNTX YTD 2022: man schenkt sich nichts:
=> die Frage (für mich) ist: schaffen es Moderna und BioNTech noch in der laufenden Sommer-Rally das alte "Gap" von Anfang des Jahres wieder zu schließen oder erst am Jahresende oder sogar noch später?
Moderna CEO: No ‘Crazy’ Deals. We’re Giving Cash to Shareholders.
https://www.marketwatch.com/articles/moderna-ceo-no-crazy-de…
...
Moderna’s CEO is feeling no pressure to acquire other companies with the $18.1 billion in cash his firm has on hand.
“Investors don’t want us to do something crazy,” the CEO, Stephane Bancel, told Barron’s Wednesday morning, after the company announced earnings results earlier in the day that beat Wall Street expectations.
Some analysts have argued that Moderna needs to undertake big-time M&A as Covid-19 vaccine demand drops worldwide. Bancel disagrees.
“They want us to create value,” he says of his investors. “So we are very happy when we tell them look, we’re returning cash to shareholders, because in the last quarter we didn’t find anything to do. We don’t want to do a big deal for the sake of doing a big deal.”
Instead, Moderna (ticker: MRNA) announced on Wednesday a new $3 billion share buyback, after buying back 9 million shares for $1.3 billion in the second quarter. An additional $1 billion in capacity remains from an earlier share buyback announced in February.
“Why would we, at this stage in the game, want to do something else that looks shiny, when we’re so close to our potentially amazing assets,” Bancel says.
...
$MRNA vs $BNTX YTD 2022: man schenkt sich nichts:
=> die Frage (für mich) ist: schaffen es Moderna und BioNTech noch in der laufenden Sommer-Rally das alte "Gap" von Anfang des Jahres wieder zu schließen oder erst am Jahresende oder sogar noch später?
Durchsuchen
04.06.24 · wallstreetONLINE Redaktion · Pfizer |
03.06.24 · wallstreetONLINE Redaktion · Adobe |
02.06.24 · wallstreetONLINE Redaktion · Coca-Cola |
02.06.24 · wallstreetONLINE Redaktion · Amazon |
01.06.24 · wO Chartvergleich · Carl Zeiss Meditec |
